Concentrated anti-inflammatory and stimulant of cartilage synthesis, repair and protection for treating joint disease in dogs
COMPOSITION
Pentosan polysulfate sodium 100 mg/mL and NAG (Acetyl Glucosamine) 160 mg/mL
ACTIONS
Synovan Injection for Dogs contains Pentosan Polysulfate sodium (PPS) which stimulates joint healing and repair, and reduces inflammation to help reverse the effects of osteoarthritis, as well as NAG (Acetyl Glucosamine) a newly approved and more advanced form of glucosamine that has been shown to improve glycosaminoglycan and hyaluronic acid synthesis compared to glucosamine (Shikhman AR et al 2009). Synovan possesses anti-inflammatory, anti-arthritic and chondroprotective properties. These beneficial effects arise from direct anti-inflammatory activity, inhibition of neutrophil migration into joints, stimulation of hyaluronic acid synthesis by synovial fibroblasts which results in a marked increase in synovial fluid volume and viscosity; stimulation of chondrocytes, and the biosynthesis of proteoglycans; and a strong fibrinolytic activity which improves the circulation in subchondral bone and periarticular structures.
Treatment using the combination of anti-arthritic agents Pentosan Polysulfate sodium and NAG (Acetyl Glucosamine) in Synovan may result in a greater anti-inflammatory effect than either active alone (Heinecke LF et al 2010, Data on File), which helps reduce joint swelling and improve mobility (Data on File).
INDICATIONS
To aid in the treatment of non-infectious joint diseases in dogs, including osteoarthritis, especially in conditions affecting multiple joints; osteochondrosis dissecans; traumatic joint and periarticular inflammation in working and racing dogs.
PRESENTATION
6 x 20 mL sterile glass multidose vial
STORAGE
Store below 25°C (Air conditioning). Do not freeze. Protect from light.
WARNINGS
Contraindicated for use in dogs with clotting defects, traumatic haemorrhage, infection, liver/kidney failure, or within 2 days of surgery.
Safety studies on the product in dogs have been done at up to 3x recommended dose rate, at weekly intervals for six weeks. Safety studies have not been carried out for longer term use. Safety studies have not been carried out in pregnant, breeding or lactating animals. Use of the product in these groups of animals is not recommended. A dose dependent increase in activated partial thromboplastin time (aPTT) was seen during the safety trials but levels returned to normal within 24 hours post treatment. The prescribing veterinarian should consider this where the patient may have suspected or diagnosed disorders that may affect haemostasis, or have concurrent medications that affect haemostasis. There was no significant difference between pre-trial and post-trial aPTT levels.
COMPOSITION
Pentosan polysulfate sodium 100 mg/mL and NAG (Acetyl Glucosamine) 160 mg/mL
ACTIONS
Synovan Injection for Dogs contains Pentosan Polysulfate sodium (PPS) which stimulates joint healing and repair, and reduces inflammation to help reverse the effects of osteoarthritis, as well as NAG (Acetyl Glucosamine) a newly approved and more advanced form of glucosamine that has been shown to improve glycosaminoglycan and hyaluronic acid synthesis compared to glucosamine (Shikhman AR et al 2009). Synovan possesses anti-inflammatory, anti-arthritic and chondroprotective properties. These beneficial effects arise from direct anti-inflammatory activity, inhibition of neutrophil migration into joints, stimulation of hyaluronic acid synthesis by synovial fibroblasts which results in a marked increase in synovial fluid volume and viscosity; stimulation of chondrocytes, and the biosynthesis of proteoglycans; and a strong fibrinolytic activity which improves the circulation in subchondral bone and periarticular structures.
Treatment using the combination of anti-arthritic agents Pentosan Polysulfate sodium and NAG (Acetyl Glucosamine) in Synovan may result in a greater anti-inflammatory effect than either active alone (Heinecke LF et al 2010, Data on File), which helps reduce joint swelling and improve mobility (Data on File).
INDICATIONS
To aid in the treatment of non-infectious joint diseases in dogs, including osteoarthritis, especially in conditions affecting multiple joints; osteochondrosis dissecans; traumatic joint and periarticular inflammation in working and racing dogs.
PRESENTATION
6 x 20 mL sterile glass multidose vial
STORAGE
Store below 25°C (Air conditioning). Do not freeze. Protect from light.
WARNINGS
Contraindicated for use in dogs with clotting defects, traumatic haemorrhage, infection, liver/kidney failure, or within 2 days of surgery.
Safety studies on the product in dogs have been done at up to 3x recommended dose rate, at weekly intervals for six weeks. Safety studies have not been carried out for longer term use. Safety studies have not been carried out in pregnant, breeding or lactating animals. Use of the product in these groups of animals is not recommended. A dose dependent increase in activated partial thromboplastin time (aPTT) was seen during the safety trials but levels returned to normal within 24 hours post treatment. The prescribing veterinarian should consider this where the patient may have suspected or diagnosed disorders that may affect haemostasis, or have concurrent medications that affect haemostasis. There was no significant difference between pre-trial and post-trial aPTT levels.
- [Zebravet_Files]:
- [Zebravet_Files]
Related Products
Footer Start
Braeside VIC 3195
AUSTRALIA
42 Kiln Street
Darra QLD 4076
AUSTRALIA